Cytokinetics, Incorporated (CYTK) Earnings Call Transcript & Summary

May 5, 2026

NASDAQ US Health Care Biotechnology earnings 28 min

Earnings Call Speaker Segments

Diane Weiser

executive
#1

Good afternoon, and thank you for being with us today on this call. Robert Blum, our President and Chief Executive Officer, is going to kick things off with a look at the quarter and what's happened recently. Andrew Callos, EVP and Chief Commercial Officer, will talk about the U.S. commercial launch of the MYQORZO as well as preparations in Europe. Fady Malik, EVP of R&D, will cover the ACACIA-HCM results. Stuart Kupfer, SVP and Chief Medical Officer, is going to share updates on the clinical development programs we have underway. Sung Lee, EVP and Chief Financial Officer, will walk through the quarter's financial picture; and then Robert will wrap up with closing remarks and go over the key milestones for the coming year. On this slide, as you can see, today's discussion is going to contain forward-looking statements, and those carry risks and uncertainties. For a discussion of these factors, please refer to our SEC filings. And with that, I'll hand the call over to Robert.

Robert Blum

executive
#2

Thanks, Diane, and I appreciate everyone being with us on today's call. For Cytokinetics, the opening quarter of 2026 proved to be an extraordinary stretch — one that, in my view, captures the dawning potential of everything we've spent more than 25 years constructing here. The headline item: we brought MYQORZO to market, our first-ever approved therapy, indicated in the United States for adults suffering from symptomatic oHCM. That achievement took many years to reach and demonstrates how firmly we remain committed to turning our science into real impact for patients. Andrew will walk you through it, but our early commercial rollout — even though it covers just part of a quarter — is running ahead of what we expected internally, posting $4.8 million in net product revenue during the first quarter. Prescriber engagement levels, how quickly REMS certifications are progressing, and the early demand we're seeing all strengthen our confidence in the substantial opportunity that lies ahead for MYQORZO, and given its obvious differentiation, we see this early traction as laying a solid groundwork for commercial success over the longer term. Turning outside the U.S., the European Commission granted approval for MYQORZO in oHCM patients during the quarter, and we are now working rapidly toward launching commercially in Europe for the first time, starting with Germany in this second quarter. MYQORZO's worldwide market is sizable, and we're carefully standing up the proper infrastructure to capture its potential. Then, naturally, comes ACACIA-HCM; earlier today we announced positive top line data from that pivotal Phase III study of aficamten in nonobstructive HCM. It was highly encouraging to observe that aficamten produced improvements in both symptoms and exercise capacity, with no fresh safety signals appearing. Fady will elaborate on the findings we disclosed, though we're thrilled about what they mean for nHCM patients, who currently have no approved treatment options. And for aficamten itself, subject to how regulatory review plays out, there may now be a chance for it to become the first product cleared to treat HCM across its full spectrum. With a statistically significant and clinically meaningful effect on both endpoints, we feel we possess a very clear understanding of the treatment effect aficamten delivers in nHCM. In light of these trial results, we intend to consult regulatory authorities, the FDA among them, about our plans to submit a supplemental NDA promptly. Several other meaningful regulatory developments for aficamten also occurred during the quarter. On the U.S. side, the FDA accepted our sNDA for MAPLE-HCM for filing and gave us a PDUFA date of November 14, 2026. We think MAPLE-HCM's results will let us speed up expansion of the prescriber base, particularly among cardiologists practicing in community settings. Beyond the U.S., we filed an MAA for aficamten in oHCM in Switzerland. Keep in mind as well that a marketing application is already under review in Canada. On top of that, our partner Sanofi continues advancing potential approvals in Hong Kong and Taiwan. When you put it all together, the strides we achieved during Q1 demonstrate what we have created in pursuit of our goal of turning into the top muscle-focused specialty biopharma firm, one determined to substantially better patients' lives by delivering our novel treatments to people globally. Looking forward, we head into the rest of 2026 carrying robust commercial momentum, belief in our pipeline and a profound sense of mission. Continued expansion of MYQORZO across the United States, moving forward with our scheduled oHCM launches throughout Europe, seeking to broaden into nHCM and pushing our muscle biology pipeline ahead stay our top priorities, each carried out with disciplined execution and close focus on capital allocation. With that said, I will hand things over now to Andrew, please.

Andrew Callos

executive
#3

Thanks, Robert. It's a real pleasure to walk everyone through how MYQORZO performed commercially in its first quarter. Patients were able to get MYQORZO starting January 27, prescriptions from HCPs showed up just days later, and the launch has gotten off to a strong beginning that went beyond what we had anticipated. Clinical evidence and differentiation are what our launch is built on. Data from SEQUOIA-HCM show that MYQORZO delivers obstruction reduction that is both rapid and sustained, along with symptom and outcome improvements that really connect with HCPs. On top of that, MYQORZO comes with a monitoring schedule that can be adapted, since echoes are allowed in a flexible window of 2 to 8 weeks, and its REMS does not call for DDI counseling. More than 80% of treating HCPs say, without any prompting, that they are aware of having reviewed the prescribing information for MYQORZO. It's encouraging to see growth continue and perceptions of clinical differentiation continue to favor MYQORZO. In the latest survey of HCPs we conducted, an even larger majority favor the clinical profile of MYQORZO, particularly among the high-volume CMI writers who were surveyed. In the survey, healthcare professionals also have a favorable opinion of MYQORZO when it comes to things like how flexibly it can be dosed, its safety and tolerability, and what the REMS program calls for. Doctors who prescribe it are reacting positively not only to how it performs clinically but also to the hands-on aspects of getting MYQORZO to patients — areas such as how easy it is to prescribe, echo monitoring, adaptability, and the absence of any DDI restrictions under REMS. It appears that HCPs regard MYQORZO as standing apart from other options. Once the FDA gave its approval at the close of December, more than 100 cardiovascular account specialists on our team began reaching out to HCPs in early January, several weeks ahead of the product's late-January launch. From then on, they have been engaging HCPs at all levels of CMI prescribing. When we first launched, our promotional and sales teams zeroed in on getting the high-volume CMI writers to prescribe more deeply — that's the segment which, historically, made up 80% of CMI prescriptions. Over 10,000 HCPs fall within our call points, though at this moment we're putting greater emphasis and allocating more calls toward those high-volume CMI writers. More than 90% of those HCPs were detailed by our sales teams during Q1. We intend to sustain this focus on high-volume prescribers until new-to-brand prescription share among them exceeds 50%, which we anticipate occurring by year-end. As soon as we see solid share gains happening with CMI writers who write at high volume, our focus will tilt more toward expanding prescribing—though we'll keep protecting our leadership position and growth within that high-volume CMI writer group. We're already seeing uptake beyond the high-volume prescribers. More than 40% of MYQORZO prescriptions in Q1 originated from a combination of low-volume CMI prescribers plus first-time CMI writers. Our field force reached an estimated 40% of those HCPs during Q1. Beyond personal and nonpersonal promotion, the surround sound strategy we use to connect with HCPs has sparked considerable interest as well—participation has been strong in our peer-to-peer physician speaker programs, and our digital advertising is drawing engagement. By the time Q1 ended, more than 2,100 individuals had signed up for the MYQORZO patient community. In addition to what our clinical data shows, we're putting effort into educating healthcare professionals about our REMS initiative and the support we offer patients, because these things aren't what HCPs typically encounter. Since the launch began, we've moved quickly to implement enhancements to those programs based on input from HCPs and the realities of clinical practice. To assess the overall progress of the launch, we've committed to reporting 3 launch metrics: how deeply and how widely prescribing is happening, along with the number of patients. We gauge how widely HCPs are prescribing by tallying the HCPs who've written prescriptions, while how deeply they prescribe is measured by the number of patients each HCP put on MYQORZO, and patient volume comes from counting the distinct patients given MYQORZO; Q1 saw robust demand, with upwards of 275 distinct HCPs writing for MYQORZO, and over half of those coming from the high-volume CMI writer group. Prescriber growth kept going through April, reaching more than 425 HCPs who've prescribed MYQORZO. All told, the CMI writers who wrote for MYQORZO averaged 2.4 prescriptions per HCP, whereas high-volume writers gave MYQORZO to about 2.6 patients per HCP. Because of some limitations in the data we can access, it's tough to state our Q1 exit share for new-to-brand patients with complete precision. That said, when our team looked internally at projected syndicated data, the picture showed MYQORZO reaching a new-to-brand Q1 exit share above 30%. For a launch this young, those figures are very encouraging. We're also encouraged by momentum building among the more than 1,400 HCPs who earned REMS certification during the quarter — something that may serve as an early signal that HCPs plan to prescribe MYQORZO. Thanks to MYQORZO's differentiated profile and the focused HCP engagement we've pursued since the year started, roughly 680 patients had been prescribed MYQORZO as Q1 2026 came to a close; by the end of April, that figure had climbed to 1,100. One more point that matters: during Q1, a paid prescription accounted for more than 70% of dispensed patients. Typically, it takes less than a fortnight for a patient to switch over to a prescription they're paying for. When it comes to both of those measures, we outperformed what we had anticipated at launch. A key driver here is our strategy of limited distribution paired with a strong emphasis on individuals using MYQORZO, and that approach has allowed us to reach a substantial share of patients receiving paid prescriptions quite early on in this launch period. While we continue to speed up the launch, our attention is also on broadening access and lowering hurdles to prescribing. As previously mentioned, we have been in discussions with payers for a considerable period about the clinical evidence generated by our clinical trial program as well as the clinical and economic burden associated with oHCM. At present, we offer comparable access covering close to 90% of Medicare lives, and we anticipate achieving parity in Medicare by Q2. We're also working on getting commercial access in place, and we anticipate covering half of commercial lives by the beginning of Q3, while staying on track to secure commercial access at parity by the time Q4 wraps up. Alongside that, we keep growing our commercial readiness and launch preparations across important markets globally. MYQORZO won approval in the EU during February, and we continue moving quickly toward our first commercial launch in Europe, which is scheduled for Germany in Q2. To support reaching that milestone, we've finished hiring and onboarding the full German team, including sales, marketing, medical, and leadership. Throughout the EU, 6 HTA dossiers have now been filed as well, and another 5 should go in during this quarter as we work toward wider patient access across Europe. An MAA was also sent to Swissmedic, and outside Europe, we remain eager for a decision from Canada during the latter half of this year. These days, Cytokinetics stands solidly as a commercial stage company. Though our U.S. launch is still in its early days, the first results have been quite encouraging. Whether in the U.S. or Europe, our commercial teams are committed to achieving excellence as our company enters this new chapter. With that said, I'll hand the call over to Fady.

Fady Malik

executive
#4

Thanks, Andrew. Earlier today, we were excited to share the topline findings from ACACIA-HCM. Both of the trial's dual primary endpoints were achieved, showing statistically significant gains from baseline through week 36 in the KCCQ clinical summary score as well as peak VO2 relative to placebo. Among those who received aficamten, KCCQ rose by 11.4 points, versus 8.4 points for the placebo group, yielding a least squares mean difference of 3 points and a p-value of 0.021. In a similar way, peak VO2 went up by 0.64 ml per kilo per minute for patients given aficamten, whereas it fell by 0.03 ml per kilo per minute among those on placebo, producing a least squares mean difference of 0.67 ml per kilo per minute and a p-value of 0.003. We also saw statistically significant gains on key secondary endpoints, such as the share of patients showing improvement in NYHA functional class, the composite Z-score for ventilatory efficiency and peak VO2, and NT-proBNP. Crucially, no new safety signals came to light. The percentage of patients who finished treatment in ACACIA-HCM was comparable whether they received aficamten or placebo. LVEF below 50% occurred in 10% of patients on aficamten, with 2 of them having a serious adverse event of heart failure. LVEF under 50% happened in 1% of those on placebo. Treatment interruptions because of LVEF below 40% took place in 3% of the aficamten-treated patients. The KCCQ improvement was strong and consistent across the treatment period for patients receiving aficamten. After washout, KCCQ fell among aficamten patients until it matched the placebo arm. At week 36, peak VO2 rose for those on aficamten while staying unchanged for those on placebo, in line with earlier aficamten trials. What makes these data especially compelling is how consistent the picture is across what the primary, secondary, and other exploratory endpoints capture. KCCQ is a patient-reported outcome reflecting how patients feel and function, their symptoms, and their quality of life, whereas peak VO2 offers an objective functional measure of exercise capacity. NYHA functional class, the first key secondary endpoint, likewise measures symptom and functional burden, though it is physician assessed, and having it improve in both symptoms and functional capacity in a meaningful way speaks to how deep aficamten's potential impact could be in this patient population. This marks a historic moment for the HCM community, and nHCM is a serious condition with no therapies ever approved. These results indicate that aficamten could change and become a treatment supporting the full spectrum of the disease; we could not be more enthusiastic about what we've seen in these top line results. I'd like to take this moment to thank our team for their relentless conduct of this trial to ensure the quality and robustness of the findings. We also want to express our deepest appreciation to the patients enrolled in ACACIA-HCM, along with their families, as well as the investigators and site personnel worldwide whose commitment and meticulous work made this study possible. Everyone involved deserves our gratitude for all they have given to this program and, by extension, to the broader HCM community. Moving forward, we intend to submit ACACIA-HCM for consideration at a forthcoming medical conference, and we are eager to share the findings more thoroughly at that point. In the meantime, beyond what was disclosed in today's press release, we cannot provide any further information. As Robert noted, we are also eager to review these findings with the U.S. FDA and other regulatory bodies; it has been a remarkably thrilling beginning to the year, to put it mildly. I will now turn things over to Stuart, who will discuss our continuing clinical trials in HCM and heart failure in greater detail.

Stuart Kupfer

executive
#5

Okay, thank you, Fady. To begin, I want to discuss the worldwide clinical studies we have underway for aficamten and HCM. Over the last three months, we kept pushing forward with three studies that collectively are establishing a broad clinical basis spanning multiple indications, regions, and patient groups. When it comes to obstructive HCM, Bayer, our collaborator, moved ahead with running CAMELLIA-HCM, which is a Phase III study assessing aficamten in individuals from Japan; and for younger patients suffering from obstructive HCM, we kept up recruitment for CEDAR-HCM, the worldwide study we're conducting that looks at aficamten in teens and younger kids. Our goal is to finish signing up participants for the adolescent group before 2026 ends. Regarding non-obstructive HCM, we carried on adding patients to the Japanese arm of ACACIA-HCM. As a matter of fact, Japan is a key market where aficamten has yet to gain approval for obstructive or nonobstructive HCM. The design of both CAMELLIA-HCM and the Japanese portion of ACACIA-HCM is meant to back possible marketing approval for both conditions there. Along those lines, I'm happy to share that aficamten was granted orphan drug status by the Japan Ministry of Health, Labor and Welfare for treating non-obstructive HCM in adults as well as obstructive HCM in pediatric patients, which mirrors the unmet need still present among these groups. Now I'll turn to our heart failure clinical development efforts. COMET-HF, the confirmatory Phase III study of omecamtiv mecarbil involving patients who have symptomatic heart failure with severely reduced ejection fraction below 30%, is moving along nicely. Every site across the U.S. and Europe has been activated, and we are striving to add more locations in China. We feel good about what we've accomplished this year so far and intend to keep enrolling people through 2026. We also carried on with AMBER-HFpEF, the Phase II study of ulacamten in patients who have symptomatic heart failure with preserved ejection fraction of at least 60%. Over the quarter, we broadened recruitment in Cohort 1 after the dose level review committee advised gathering additional data at the existing doses, and we anticipate finishing patient enrollment for Cohort 1 during the latter half of this year. Throughout all these initiatives, we stay committed to disciplined implementation and are heartened by the strides we keep making toward building what we think will become a top-tier specialty cardiology franchise. With that said, I'll hand things over to Sung.

Sung Lee

executive
#6

Thanks, Stuart. Let's start with revenue. For the first quarter, total revenues came in at $19.4 million, versus $1.6 million during the same period in 2025. During Q1, we booked $4.8 million in net product revenues for MYQORZO, reflecting roughly 9 weeks of commercial sales after the U.S. launch near the end of January. As Andrew mentioned earlier, demand for MYQORZO was strong, and net product revenue reflects more than 70% of dispensed patients being on a paid prescription, with the remainder getting drug through our 30-day free trial, bridge, or patient assistance programs. We anticipate that most patients receiving MYQORZO via free trial and bridge programs will move to paid prescriptions in a timely manner, and we expect this pattern to recur in future quarters. Other items contributing to total revenues in Q1 include $2.6 million in collaboration revenue, versus $1.6 million during the same period in 2025, plus $11.9 million from achieving a milestone under the Bayer license agreement tied to the first commercial sale of MYQORZO in the U.S. Now to expenses. R&D expenses in Q1 were $95.5 million, versus $98.3 million during the same period in 2025. That decrease was mainly driven by higher clinical trial activity in 2025, partly offset by higher personnel-related costs in 2026. SG&A expense in Q1 was $104.9 million, versus $57.4 million during the same period in 2025. That increase was mainly driven by external costs tied to the commercial launch of MYQORZO, the U.S. sales force, and higher nonsales personnel-related costs, including stock-based compensation. Cost of goods sold in Q1 2026 was $0.2 million. Collaboration cost of revenues in Q1 2026 was $2.4 million, versus $1.6 million during the same period in 2025. Collaboration cost of revenues includes cost reimbursement as well as costs incurred related to manufacturing drug supplies for collaboration partners. Net loss in Q1 2026 was $206 million, or $1.67 per share, versus a net loss of $161.4 million, or $1.36 per share, during the same period in 2025. Now to the balance sheet: we closed Q1 with roughly $1.1 billion in cash and investments, versus $1.2 billion at the close of Q4 2025. Cash and investments fell by roughly $144 million during Q1 2026. Now to our financial guidance: we are maintaining our full year 2026 financial guidance, with GAAP combined R&D and SG&A expense expected to land between $830 million and $870 million. Stock-based compensation included in the GAAP combined R&D and SG&A expense is expected to land between $120 million and $130 million. Excluding stock-based compensation from the GAAP combined R&D and SG&A expense gives a range of $700 million to $750 million. Now that we've shared the good top-line data from ACACIA-HCM, we'll come back to you down the road regarding how this progress might affect our financial guidance. Going forward, our attention stays on allocating capital carefully and putting our investment dollars first toward rolling out MYQORZO across the U.S. and Europe, pushing our development pipeline forward, and funding our muscle biology platform along with our research pipeline. On that note, I'll turn things back over to Robert.

Robert Blum

executive
#7

Thanks, Sung. For Cytokinetics, this quarter is one we'll look back on for a very long time. The very first medicine from our company reached patients throughout the United States; we recorded our first product sales revenue; we kept advancing our preparations for future launches across the globe; and then, only this morning, we shared positive top line results from ACACIA-HCM — results that, in our view, may open a new chapter for those living with nHCM. I take enormous pride in all we've accomplished in 2026 so far, and what lies ahead leaves me feeling even more energized. The HCM opportunity has never looked more promising, and our ability to deliver has never been greater. We're keen to keep you updated as the year unfolds; so let me now walk through our 2026 milestones. Where aficamten is concerned, we expect meetings with regulatory agencies, including the U.S. FDA, to discuss the ACACIA-HCM data and our potential plans for submitting a supplemental NDA. We expect to launch MYQORZO in Germany in this second quarter of 2026. We expect that we may secure FDA approval of the supplemental NDA for MAPLE-HCM in Q4 2026; we expect to complete enrollment in the adolescent cohort of CEDAR-HCM during the fourth quarter of this year, and we expect that we may receive approval from Health Canada in the second half of this year. Turning to omecamtiv mecarbil, we expect to continue enrolling patients in the conduct of COMET-HF throughout 2026. As for ulacamten, we expect to complete patient enrollment in Cohort 1 of AMBER-HFpEF in 2H 2026. And as for CK-089, we expect to begin conducting a second Phase I study; and finally, as for our preclinical development and our ongoing research, we expect to continue those activities targeting additional muscle biology-focused programs all through the year. Also, cost of goods sold for the first quarter of 2026 came to $200,000. As a reminder, there will be no question-and-answer session after these prepared remarks on today's call. We want to thank each of you, every participant on this call today, for your continued support and your interest in Cytokinetics. And operator, with that, we can now please conclude the call.

Operator

operator
#8

This concludes today's call. Thank you for attending. You may now disconnect.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Cytokinetics, Incorporated transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Cytokinetics, Incorporated earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Cytokinetics, Incorporated or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.